Ozmosi | GC-1109 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

GC-1109

Alternative Names: gc-1109, gc1109, gc 1109
Clinical Status: Inactive
Latest Update: 2025-11-03
Latest Update Note: News Article

Product Description

GC1109 targets as its antigen the anthrax toxin which, in infection, serves as a receptor binder.

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Green Cross
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Anthrax

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT01867957

 GC1109_P1_v1.2

P1

Completed

Anthrax

2009-12-01

2019-03-19

Treatments

NCT01624532

 GC1109

P2

Completed

Anthrax

2022-08-02

2023-01-05

Recent News Events

Date

Type

Title

11/03/2025

News Article

 GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'

10/09/2023

News Article

 Water and Wastewater Treatment Market 2023 Share, Scope, Stake, Trends, Industry Size, Sales & Revenue, Growth, Opportunities Report 2032

05/05/2023

PubMed

 Immunogenicity and Protective Efficacy of Recombinant Protective Antigen Anthrax Vaccine (GC1109) in A/J Mice Model.

02/11/2020

PubMed

 Evaluation of the protective efficacy of recombinant protective antigen vaccine (GC1109)-immunized human sera using passive immunization in a mouse model.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions